GoodRx widens GLP‑1 access

A weight-loss pill that just got approved on April 1 is already showing up at ordinary pharmacy counters, and GoodRx says cash-paying patients can now get Eli Lilly’s Foundayo starting at $149 a month through its network. GoodRx also says Lilly’s Zepbound KwikPen starts at $299 a month for eligible self-pay patients at more than 70,000 U.S. pharmacies. (finance.yahoo.com) That is a change in where the deal happens. Instead of hunting through a drugmaker website, a mail-order program, or a telehealth bundle, a patient can now look up a price through GoodRx and fill the prescription at a neighborhood chain or grocery pharmacy. (finance.yahoo.com) GoodRx is not making the drug. GoodRx is acting like a giant pricing and routing layer, connecting Lilly’s self-pay offers to a pharmacy network that already covers tens of thousands of stores. (morningstar.com) Foundayo is Lilly’s brand name for orforglipron, a once-daily pill for adults with obesity or adults who are overweight and have at least one weight-related health condition. The Food and Drug Administration approved it on April 1, 2026, and the agency said the decision came 50 days after filing under its National Priority Voucher pilot. (fda.gov) Lilly says Foundayo is the only glucagon-like peptide-1 pill for weight loss that can be taken any time of day without food or water restrictions. That matters because Novo Nordisk’s oral semaglutide products have had stricter timing rules, which made the “pill instead of shot” option less simple than it sounded. (prnewswire.com) In Lilly’s ATTAIN-1 trial, adults on the highest Foundayo dose lost an average of 27 pounds, and the American Journal of Managed Care reported placebo-adjusted weight reduction of roughly 9 to 11 percentage points at 72 weeks. Those numbers are why drugmakers are racing to turn weight-loss shots into mass-market pills. (prnewswire.com) (ajmc.com) The Zepbound side of this deal matters for a different reason. Zepbound KwikPen is Lilly’s single-patient-use multi-dose pen, so one device covers multiple weekly injections instead of the older routine of handling separate single-dose pens. (zepbound.lilly.com) Lilly had already started pushing that pen into retail in March, with self-pay pricing beginning at $299 for the 2.5 milligram starter dose, $399 for 5 milligrams, and $449 for higher maintenance doses under program terms. GoodRx adds a national price-display layer on top of that rollout, which makes the offer easier to find before a patient ever reaches the counter. (zepbound.lilly.com) (ir.kroger.com) The bigger fight here is over the cash market, not the insured market. Lilly is trying to build a lane for people whose health plan does not cover obesity drugs, and GoodRx is useful because millions of Americans already treat it as a price-comparison tool for prescriptions. (finance.yahoo.com) (goodrx.com) That means the real story is not just a new coupon. Lilly launched Foundayo through LillyDirect on April 1, and by April 9 it had also lined up GoodRx, telehealth partners, and broad pharmacy distribution, which is unusually fast for a brand-new obesity drug launch. (prnewswire.com) (fiercehealthcare.com) If this works, the next phase of the weight-loss drug market may look less like a specialty-clinic bottleneck and more like buying a blood-pressure prescription: check the cash price, send the prescription, pick it up nearby. GoodRx’s 70,000-pharmacy footprint is what makes that shift plausible right now, not someday. (finance.yahoo.com)